- Leads global preclinical projects to discover and optimize drugs up to the IND stage. - Leads translational R&D teams in Rare Diseases to support Ph2 and Ph3 clinical development, 
formulating rationales for next indications, combinations, and sequence of treatments. - Member of governance committees: scientific research and deal flow- Serves as company expert in Rare Diseases, acting as the scientific lead for due diligence, licensing 
activities and other corporate needs and inquiries, supporting Business Development. - Identifies and manages external collaborations with KOLs, including AdBoard support.

- Head of the in vitro endocrinology research laboratory at Ipsen Bioscience, including scientific direction, operation, and personnel management of a team of seven scientists. Early therapeutic concept assessment, lead identification, and optimization of peptide therapeutics. - Global liaison with preclinical research teams across company sites. - Coordination of local and international collaborations with academic partners and other companies. - Evaluation and supervision of CROs.

- Scouting and evaluation of patenting opportunities and drafting new patent applications. - Building up teams and programs for new startups. - Coordination of translational research projects in the fields of Psychiatry, Neuroendocrinology, Obesity, 
and Cancer in collaboration with the pharmaceutical industry. - Supervision of PhD students and technical assistants.

- Supervision of drug discovery projects for major depression, schizophrenia, and multiple sclerosis, including target validation, assay development, and generation of monoclonal antibodies for therapy. - Translational science lead in Ph 1 and Ph 2 programs. Supervision of scientific collaborations with academic partners. - Scientific due diligence of licensing opportunities. Evaluation of patentability and patenting strategy.

- Principal Investigator of a team working on gene discovery and target validation using mouse models of depression, anxiety and antidepressant response in combination with microarray and proteomic analysis. - Pioneer in the development of in vivo siRNA treatment in the mouse brain combined with behavioral tests as a target validation tool. Scientific due diligence for the foundation of Affectis Pharmaceuticals.

Characterization of the signaling pathways involved in the interactions between the brain, the endocrine and the immune system during bacterial infection in humans and in animal models of septic shock.